Ecofibre has become the second cannabis company to see its hopes of registering an over-the-counter CBD product thrown into doubt after a clinical trial failed to produce the desired results.

The firm said its CANN-Sleep phase 3 clinical trial – conducted by Southern Cross University’s National Centre for Naturopathic Medicine – did not show sufficient differences between Ecofibre’s schedule 3 candidate and a placebo.

Join the Cannabiz revolution

Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?

This article is included with our Premium subscription.

Join or login
Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh.
Vel turpis nunc eget lorem dolor sed. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh. Nisl nunc mi ipsum faucibus vitae.
Elementum integer enim neque volutpat ac tincidunt vitae semper quis. Eu lobortis elementum nibh tellus molestie nunc. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh. Magnis dis parturient montes nascetur ridiculus. Dui id ornare arcu odio ut sem. Nisl nunc mi ipsum faucibus vitae.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Steve has reported for a number of consumer and B2B titles over a journalism career spanning more than three decades. He is a regulator contributor to health journal, The Medical Republic, writing on...

Join the Conversation

2 Comments

  1. What quantity of CBD was the daily dose for this trial? Anyone shed a little more light on the methodology/approach?

  2. It’s a real shame. The max allowable daily dose of CBD did seem too low. I wonder if the desire of trial patients, for CBD to be proven efficacious, plays into the placebo? Who else currently has active trials going?